文献速递血栓与止血

减剂量直接口服抗凝药在静脉血栓栓塞症延长期治疗中的系统评价与荟萃分析

Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis.
PubMed 文献 · J Thromb Haemost · 2018-06-17

系统评价与荟萃分析比较减剂量直接口服抗凝药(DOACs)与全剂量DOACs及阿司匹林或安慰剂在静脉血栓栓塞症延长期治疗中的疗效与安全性。减剂量DOACs预防1年复发性VTE的疗效与全剂量相当(RR 1.12,95%CI 0.67-1.87),优于阿司匹林或安慰剂(RR 0.26,95%CI 0.14-0.46);大出血或临床相关非大出血与阿司匹林或安慰剂相似(RR 1.19,95%CI 0.81-1.77);与全剂量DOACs相比有出血更少趋势(RR 0.74,95%CI 0.52-1.05)。作者认为减剂量DOACs可能有效,但需进一步长期研究。

要点

  • 减剂量DOACs预防1年复发性VTE疗效与全剂量相当(RR 1.12,95%CI 0.67-1.87)。
  • 减剂量DOACs优于阿司匹林或安慰剂预防复发性VTE(RR 0.26,95%CI 0.14-0.46)。
  • 减剂量DOACs与阿司匹林或安慰剂出血风险相似(RR 1.19,95%CI 0.81-1.77)。

核心结论

  • 延长期减剂量DOACs治疗VTE可能和全剂量一样有效,大出血发生率与阿司匹林或安慰剂相似,但需要进一步长期研究。

研究设计与样本

  • 两项试验符合预设纳入标准,疗效结局分析5847例患者,安全性结局分析5842例患者。

主要发现

  • 减剂量DOACs预防1年复发性VTE与全剂量治疗同样有效(RR 1.12,95%CI 0.67-1.87),且比阿司匹林或安慰剂更有效(RR 0.26,95%CI 0.14-0.46)。
  • 减剂量DOACs组与阿司匹林或安慰剂组的大出血或临床相关非大出血发生率相似(RR 1.19,95%CI 0.81-1.77)。
  • 减剂量DOACs与全剂量DOACs比较,出血有减少趋势(RR 0.74,95%CI 0.52-1.05)。

临床怎么用

  • 作者认为,在VTE治疗延长期,减剂量DOACs可能是一个有吸引力的选择。

局限性

  • 作者结论指出需要进一步长期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials In venous thromboembolism (VTE), benefits of extended treatment are balanced by bleeding risks. This is a meta-analysis of reduced-dose direct oral anticoagulants (DOACs) in extended treatment. Reduced-dose DOACs are as effective as full anticoagulation with bleeding risks similar to placebo. Reduced-dose DOACs are an attractive option for patients in the extended phase of VTE treatment. SUMMARY: Background Extended-duration anticoagulation is beneficial for preventing recurrent venous thromboembolism (VTE). Reduced-dose direct oral anticoagulants (DOACs) may be preferable if they preserve efficacy and cause less bleeding. We conducted a systematic review and meta-analysis of trials comparing reduced-dose DOACs with full-dose DOACs and aspirin or placebo in the extended phase of VTE treatment. Methods A literature search was conducted by use of the MEDLINE, EMBASE and CINAHL databases, supplemented by hand-searching. One thousand three hundred and ninety-nine titles were screened, with data from accepted studies being extracted by two independent reviewers. Major outcomes analyzed included recurrent VTE and major and clinically relevant non-major bleeding events, presented as risk ratios (RRs) and 95% confidence intervals (CI). Results Two trials met the prespecified inclusion criteria. Data from 5847 patients were analyzed for efficacy outcomes, and from 5842 patients for safety outcomes. Reduced-dose DOACs were as effective as full-dose treatment in preventing recurrent VTE at 1 year (RR 1.12 [95% CI 0.67-1.87]), and more effective than aspirin or placebo (RR 0.26 [95% CI 0.14-0.46]). Rates of major or clinically relevant non-major bleeding events were similar between patients receiving reduced-dose DOACs and and those receiving aspirin or placebo (RR 1.19 [95% CI 0.81-1.77]). There was a trend towards less bleeding when reduced-dose and full-dose DOACs were compared (RR 0.74 [95% CI 0.52-1.05]). Conclusions Extended-duration treatment of VTE with reduced-dose DOACs may be as efficacious as full-dose treatment, with rates of major bleeding being similar to those in patients receiving treatment with aspirin or placebo, but further long-term studies are needed.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, et al. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2018. PMID: 29772108. doi:10.1111/jth.14156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。